. 2023 Jan 12;48(6):929–935. doi: 10.1038/s41386-022-01527-7

Table 3.

Spearman correlations among changes in variables from baseline to week 12 in the 4 g/d treatment group.

	IDS-C30	Hs-CRP	IL-6 (PBMC)	TNF (PBMC)	5-HEPE	11-HEPE	12-HEPE	15-HEPE	18-HEPE	4-HDHA	7-HDHA	14-HDHA	17-HDHA	5-HETE	11-HETE	12-HETE	15-HETE	PGE₂	TXB₂
IDS-C30	1	0.61*	0.11	0.17	−0.21	−0.57	−0.20	−0.71*	−0.80**	−0.27	−0.04	−0.15	−0.77*	−0.08	−0.17	−0.06	0.03	−0.40	−0.34
Hs-CRP		1	−0.10	0.37	−0.30	−0.50	−0.34	−0.68*	−0.73*	−0.11	−0.31	−0.15	−0.28	0.10	0.02	0.01	−0.11	−0.12	−0.06
IL-6 (PBMC)			1	0.21	18	0.09	−0.22	0.12	−0.04	−0.26	−0.30	−0.17	−0.13	0.07	0.04	−0.10	0.03	0.65	0.20
TNF (PBMC)				1	−0.73*	−0.60	−0.29	−0.64*	−0.07	−0.48	−0.75*	−0.05	−0.53	−0.39	−0.15	−0.03	−0.13	−0.41	0.58
5-HEPE					1	0.89**	0.65*	0.69*	0.32	0.89**	0.93***	0.47	0.87**	0.78**	0.62^	0.38	0.61*	−0.17	−0.37
11-HEPE						1	0.60	0.87**	0.55	0.79**	0.73*	0.46	0.79**	0.67*	0.67*	0.35	0.57	0.07	−0.07
12-HEPE							1	0.40	0.52	0.65*	0.75*	0.95***	0.89**	0.46	0.39	0.86**	0.60	−0.41	0.05
15-HEPE								1	0.57	0.51	0.54	0.23	0.51	0.37	0.29	0.11	0.18	0.00	−0.17
18-HEPE									1	0.33	0.23	0.43	0.39	−0.09	0.08	0.29	0.00	0.24	0.04
4-HDHA										1	0.83**	0.54	0.83**	0.79**	0.74*	0.40	0.68*	−0.38	−0.20
7-HDHA											1	0.56	0.92***	0.74*	0.50	0.47	0.60	−0.39	−0.48
14-HDHA												1	0.79**	0.42	0.43	0.95***	0.66*	0.32	0.24
17-HDHA													1	0.73*	0.66*	0.72*	0.77**	−0.24	−0.09
5-HETE														1	0.85**	0.34	0.86**	−0.17	−0.38
11-HETE															1	0.40	0.91	0.14	0.08
12-HETE																1	0.67	−0.23	0.34
15-HETE																	1	0.00	0.05
PGE₂																		1	0.62*
TXB₂																			1

*p < 0.05, **p < 0.01, ***p < 0.001.